BeyondSpring Inc. Stock price

Equities

BYSI

KYG108301006

Biotechnology & Medical Research

Delayed Nasdaq 03:59:11 2023-12-06 pm EST Intraday chart for BeyondSpring Inc. 5-day change 1st Jan Change
0.8725 USD +0.29% -0.85% -53.59%
Sales 2023 * 1.35M Sales 2024 * - Capitalization 34.03M
Net income 2023 * -37M Net income 2024 * - EV / Sales 2023 *
25,2x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-1,86x
P/E ratio 2024 *
Employees 73
Yield 2023 *
-
Yield 2024 *
-
Free-Float 73.53%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.29%
1 week-0.85%
Current month+2.05%
1 month-10.32%
3 months-4.06%
6 months-30.20%
Current year-53.59%
More quotes
1 week
0.81
Extreme 0.81
0.92
1 month
0.80
Extreme 0.8
1.04
Current year
0.65
Extreme 0.6534
3.45
1 year
0.55
Extreme 0.55
3.45
3 years
0.54
Extreme 0.542
33.00
5 years
0.54
Extreme 0.542
33.00
10 years
0.54
Extreme 0.542
48.49
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 2012
Chief Tech/Sci/R&D Officer 79 2015
Members of the board TitleAgeSince
Director/Board Member 55 2018
Chief Executive Officer 52 2012
Director/Board Member 54 2016
More insiders
Date Price Change Volume
23-12-06 0.8725 +0.29% 28,807
23-12-05 0.87 -2.13% 8,202
23-12-04 0.8889 +2.17% 16,636
23-12-01 0.87 +1.75% 41,241
23-11-30 0.855 -2.84% 37,872

Delayed Quote Nasdaq, December 06, 2023 at 03:59 pm EST

More quotes
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on using its technology platform for drug discovery and the development of therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.8725USD
Average target price
1.25USD
Spread / Average Target
+43.27%
Consensus
1st Jan change Capi.
-53.59% 34 M $
+22.40% 91 081 M $
+15.84% 88 879 M $
-5.98% 31 581 M $
+23.08% 27 228 M $
-32.54% 24 090 M $
-24.52% 21 026 M $
-17.26% 18 954 M $
+0.03% 11 738 M $
+22.68% 11 133 M $
Bio Therapeutic Drugs
  1. Stock
  2. Equities
  3. Stock BeyondSpring Inc. - Nasdaq
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer